Skip to main content

Stable Isotope Tracer Ultrafiltration Assay (SITUA)

The complexity of nanomedicine drug formulations poses unique scientific challenges. In contrast to conventional small molecule formulations, the active pharmaceutical ingredient (API) in a systemically administered nanomedicine formulation exists in several forms: (a)  nanomedicine-encapsulated, (b) unencapsulated, free/unbound, and (c) unencapsulated, protein-bound. While the free, unbound form is considered the only biologically active form of the API, all three fractions are important in characterizing a nanomedicine’s pharmacokinetics—especially in evaluation of bioequivalence (BE) (pharmacokinetic similarity). Existing methods to measure these various nanomedicine fractions (e.g. solid phase extraction, conventional ultrafiltration, etc.) are not ideal due to a variety of shortcomings. NCL has developed a novel bioanalytical technique to fractionate the various subpopulations of a nanomedicine in plasma, in an effort to fulfill this unmet need and facilitate regulatory review of generic nanomedicines/nanosimilars—the Stable Isotope Tracer Ultrafiltration Assay (SITUA). This method is now available as a service to nanomedicine developers. Developers can select from one of two studies, designed to further advance the preclinical development of their formulation.

 

Image depicts a micellar nanoparticle with drug molecule encapsulated, in equilibrium with the free drug molecule and protein-bound drug molecule.

Systemically administered nanomedicine formulations exist in three forms, (a) nanomedicine-encapsulated, (b) unencapsulated, free/unbound, and (c) unencapsulated, protein-bound.

 

Technical Service NCL-01: An in vitro drug release study in human plasma using the SITUA

The in vitro drug release study will provide concentrations of encapsulated, free/unbound, and protein-bound drug and is ideal for formulation optimization and lot release.

 

Technical Service NCL-02: A pharmacokinetic study in rats using the SITUA

Blood samples will be collected at various timepoints for analysis of encapsulated, free/ unbound, and protein-bound drug concentrations, as well as noncompartmental pharmacokinetic analysis to complement preclinical bioequivalence evaluation.

 

SITUA Technical Details

The assay uses a stable isotopically labeled version of the nanomedicine-encapsulated drug and an ultrafiltration technique. When spiked into plasma or other matrix, the stable isotope labeled drug equilibrates with protein and nanomedicine identical to the unlabeled, normoisotopic drug. Therefore, the ultrafiltrate fraction of the isotopically labeled drug represents a reliable measurement of the free drug fraction. The plasma protein bound, unencapsulated, and encapsulated nanomedicine fractions can then be easily calculated.

More details on the SITUA can be found in the following publications.

  • Skoczen S, McNeil SE, and Stern ST, Stable isotope method to measure drug release from nanomedicines. J Control Release, 2015, 220(Pt A), 169-174.  PMID: 26596375
  • Skoczen SL, Stern ST. Improved ultrafiltration method to measure drug release from nanomedicines utilizing a stable isotope tracer, in Characterization of nanoparticles intended for drug delivery, S. McNeil, Editor. Methods in Molecular Biology. Vol. 1628, 2018, Humana Press, New York, NY. p. 223-239.  PMID: 29039106
  • Skoczen SL, Snapp KS, Crist RM, Kozak D, Jiang X, Liu H, Stern ST, Distinguishing pharmacokinetics of marketed nanomedicine formulations using a stable isotope tracer assay. ACS Pharmacol Transl Sci. 2020, 3(3), 547-558.  PMID: 32566919

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Stable Isotope Tracer Ultrafiltration Assay (SITUA) was originally published by the National Cancer Institute.”